Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $74,202.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,350 shares of the stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $34,937.70.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $23.90 on Friday. The company’s 50-day simple moving average is $25.09 and its two-hundred day simple moving average is $24.28. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The company has a market capitalization of $1.17 billion, a P/E ratio of -12.58 and a beta of 1.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC lifted its holdings in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics in the third quarter worth about $256,000. Verition Fund Management LLC bought a new position in Enliven Therapeutics during the 3rd quarter worth about $271,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $322,000. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ELVN. Robert W. Baird raised their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, BTIG Research began coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.